LFB in the news
Biopharma Group rare diseases
Tamtam found 19 recent articles about LFB.
- Ancienne de Dassault Systèmes, la polytechnicienne Claire Biot prend la tête du laboratoire français LFB
Claire Biot, former Dassault Systèmes executive, has been appointed interim CEO of LFB, a French biopharmaceutical company.
- A la tête de l’usine du LFB à Arras, Elisabeth Perrin mise sur la force du collectif
Elisabeth Perrin has been appointed director of the new LFB plant in Arras, a 750-million-euro investment designed to triple immunoglobulin production for rare diseases.
- Gard - LFB bomanufacturing consolide son partenariat avec le groupe allemand Sartorius
LFB biomanufacturing reinforces its partnership with Sartorius to support biopharmaceutical companies in drug development, aiming to reduce risks and streamline processes.
- [Communiqué] Gard : renforcement de la collaboration entre LFB Biomanufacturing et Sartorius, à Alès
LFB Biomanufacturing and Sartorius are collaborating to streamline drug development for biopharmaceutical companies, handling various stages from genetic construction to active substance production.
- Les dons de plasma sanguin revendus à l'industrie pharmaceutique ? C'est trompeur
The French plasma donation system is heavily regulated and non-profit, with the EFS transferring plasma to the state-owned LFB at an administrative price to cover costs and primarily serve the French market, despite circulating misinformation regarding commercialization.
- Arras : l'usine géante du LFB sort ses premiers médicaments
LFB's new factory near Arras has begun producing plasma-derived medicines, employing over 500 people and strengthening its position as a top French and global producer.
- « C’était l’un des plus gros chantiers d’Europe » : près d’Arras, l’usine géante du LFB sort ses premiers médicaments
LFB has launched a huge new pharmaceutical plant near Arras, now producing its first medicines.
- Le Laboratoire LFB migre vers Nutanix et OVHCloud en 4 mois
LFB rapidly migrated its IT infrastructure to Nutanix and OVHCloud within four months, ensuring data sovereignty and operational continuity while boosting agility and deployment speed.
- Arras : LFB débute la commercialisation de ses immunoglobulines
LFB has launched immunoglobulin production at its new Arras plant to boost French market share and reduce plasma import dependence, investing heavily in production capacity and R&D for home-administered treatments.
- A Arras, l'usine géante de médicaments à base de plasma de LFB commence à fournir les patients
LFB's new plasma drug factory in Arras began supplying patients, aiming to expand production and market share amid growing demand and government support.
- L’usine LFB d’Arras veut recruter 130 collaborateurs dans l’année à venir
LFB's Arras pharmaceutical factory aims to hire 130 new staff in the next year, growing from 250 employees as of early 2023.
- Ekno se met dans la peau d’un technicien pour LFB
Ekno produces employer branding videos for LFB to address a shortage of maintenance technicians.
- Biolog-id équipe un centre du LFB avec un portique de traçabilité par radio-identification
Biolog-id implemented a high-frequency RFID system at LFB to automate and secure blood product traceability from reception to patient delivery.
- Biolog-id équipe un centre du LFB avec un portique de traçabilité par radio-identification
Biolog-id implemented a high-frequency RFID system at LFB to automate and ensure precise traceability of blood products from reception to patient delivery.
- Rupture de traitements vitaux : quels sont les médicaments concernés par la pénurie ?
LFB is facing production slowdowns causing shortages of critical blood-derived medicines until mid-2026 due to factory upgrades, prompting health authorities to manage supplies and recommend treatment adjustments.
- Pourquoi un médicament dérivé du sang fabriqué à Lille est-il en rupture ?
LFB's Lille facility paused production of plasma-derived drugs, causing supply shortages, but production is now resuming with plans to expand capacity.
- Des médicaments issus du sang seront en rupture jusqu’à mi-2026
France will face shortages of key blood-derived medicines until mid-2026 due to LFB's Lille plant modernization, with sales limits imposed to manage supply.
- Plusieurs médicaments dérivés du sang subissent des tensions d’approvisionnement, selon l’ANSM
LFB faces supply tensions for several blood-derived medicines due to equipment upgrades, with measures in place to ensure care continuity and plans to expand production capacity by 2024.
- Actualité - Recommandations dans l’utilisation d’alternatives à certains médicaments dérivés du sang du LFB
LFB faces supply shortages of some blood-derived medicines due to production upgrades, prompting sales limits and guidance on alternative treatments.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like LFB?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies